<DOC>
	<DOCNO>NCT00587223</DOCNO>
	<brief_summary>The purpose study evaluate use Apligraf treatment nonhealing wound subject dystrophic junctional epidermolysis bullosa . Apligraf evaluate efficacy safety compare conventional nonadherent dressing . A matched-pair design use evaluate Apligraf treatment versus conventional treatment 68 study pair .</brief_summary>
	<brief_title>Safety Efficacy Apligraf Nonhealing Wounds Subjects With Junctional Dystrophic Epidermolysis Bullosa ( EB )</brief_title>
	<detailed_description />
	<mesh_term>Epidermolysis Bullosa</mesh_term>
	<mesh_term>Epidermolysis Bullosa Dystrophica</mesh_term>
	<mesh_term>Epidermolysis Bullosa , Junctional</mesh_term>
	<criteria>Subject 2 65 year age . Subject clinical histological diagnosis junctional dystrophic EB document electron microscopy immunofluorescence microscopy . Subject least two nonadjacent EB lesion , least 4 cm apart . The two select EB lesion must relatively match term diagnosis , location , level erosion size . Lesions may limb . Subject dystrophic junctional EB lesion 1044 cm2 present least 6 week . For purpose study , lesion define wound result post blister erosion . Subject female childbearing potential ( female &gt; 10 year age ) must document negative urine serum pregnancy test . Sexually active female must practice medically proven form contraception course study period . Subject legal guardian must read , understood sign institutional review board ( IRB ) approve Informed Consent Form Assent Form . Subject and/or legal guardian must able willing follow study procedure instruction . Subject lesion sol , posterior thigh gluteus maximus . Subject whose lesion heal 20 % great area post debridement ( applicable ) Baseline Screen ( Visit 1 ) post debridement Day 0 ( Visit 2 ) determine wound tracing . Subject uncontrolled diabetes mellitus ( glycosylated HbA1C &gt; 10 % ) , cancer ( biopsy confirm active malignancy ) , positive HIV test . Subject child ( &lt; 18 year age ) currently receive receive oral steroid therapy exceed total daily dose 0.5mg/kg two week , radiation immunosuppressive therapy would interfere wound heal within past four week . Subject adult ( &gt; 18 year age ) currently receive receive chronic high dose steroid therapy exceed total daily dose 20mg two week , radiation immunosuppressive therapy would interfere wound heal within past four week . Subject currently receive topical steroidal therapy within 30 day screen . Inhaled steroid allow . Subject presence acute infection area intend treatment . Subject history squamous cell carcinoma . Known hypersensitivity bovine collagen component Apligraf agarose ship medium . Subject lactate pregnant ( hCG positive determine lab test ) . Subject child ( &lt; 18 year age ) liver ( ALT/SGPT , ALP , AST/SGOT , bilirubin , total protein , LDH ) and/or renal function ( BUN creatinine ) test &gt; 2 x upper limit normal ( ULN ) . Albumin &lt; 2.0 mg/dL . Subject adult ( &gt; 18 year age ) liver ( ALT/SGPT , ALP , AST/SGOT , bilirubin , total protein , LDH ) and/or renal function ( BUN creatinine ) test &gt; 2 x upper limit normal ( ULN ) . Albumin &lt; 2.0 mg/dL . Subject enrol wound investigational device study disease within past four week . Subject receive investigational drug biological treatment within three month . Subject previously treat Apligraf , Dermagraft cell therapy target site . Subject history alcohol substance abuse within previous year , could interfere study compliance inability attend schedule study visit compliance home dressing change . Subject , opinion investigator , reason list , able complete study per protocol .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>